WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of new ATC codes decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code Implementation in the ATC/DDD index
A02BD12rabeprazole, amoxicillin and clarithromycin01.02.20192020
A02BD13rabeprazole, amoxicillin and metronidazole01.02.20192020
A02BD14vonoprazan, amoxicillin and clarithromycin01.02.20192020
A02BD15vonoprazan, amoxicillin and metronidazole01.02.20192020
A03FA09 mosapride01.02.20192020
A07AA13rifamycin01.02.20192020
A10BK06sotagliflozin01.02.20192020
A16AB19pegvaliase01.02.20192020
B01AF04betrixaban01.02.20192020
B02AB05ulinastatin01.02.20192020
B03AA12ferrous sodium citrate01.02.20192020
B03XA06luspatercept01.02.20192020
B06AX01crizanlizumab01.02.20192020
C08CA51amlodipine and celecoxib01.02.20192020
C09BX04perindopril, bisoprolol and amlodipine01.02.20192020
C09DB09fimasartan and amlodipine01.02.20192020
C09DX07irbesartan, amlodipine and hydrochlorothiazide01.02.20192020
C10BA07rosuvastatin and omega-3 fatty acids01.02.20192020
C10BA08atorvastatin and omega-3 fatty acids01.02.20192020
C10BX16rosuvastatin and fimasartan01.02.20192020
D11AA01glycopyrronium01.02.20192020
G04CA54tamsulosin and tadalafil01.02.20192020
H01CC03elagolix01.02.20192020
J01GB14plazomicin01.02.20192020
J04AB06enviomycin01.02.20192020
J05AH04laninamivir01.02.20192020
J05AP10elbasvir01.02.20192020
J05AP11grazoprevir01.02.20192020
J05AP58daclatasvir, asunaprevir and beclabuvir01.02.20192020
J05AR25lamivudine and dolutegravir01.02.20192020
J05AX24tecovirimat01.02.20192020
J05AX25baloxavir marboxil01.02.20192020
J05AX26amenamevir01.02.20192020
J05AX27favipiravir01.02.20192020
L01XC33cemiplimab01.02.20192020
L01XE51acalabrutinib01.02.20192020
L01XE52quizartinib01.02.20192020
L01XE53larotrectinib01.02.20192020
L01XE54gilteritinib01.02.20192020
L01XX62ivosidenib01.02.20192020
L01XX63glasdegib01.02.20192020
L01XX64entinostat01.02.20192020
L02BB06darolutamide01.02.20192020
L04AA41imlifidase01.02.20192020
L04AA42siponimod01.02.20192020
L04AA43ravulizumab01.02.20192020
L04AB07opinercept01.02.20192020
L04AC18risankizumab01.02.20192020
N02CX09fremanezumab01.02.20192020
N06AX27 1)esketamine01.02.20192020
N06BA14solriamfetol01.02.20192020
N07XX15inotersen01.02.20192020
P01BA07tafenoquine01.02.20192020
P02CX03moxidectin01.02.20192020
S01AA28vancomycin01.02.20192020
S01EE06 latanoprostene bunod01.02.20192020
S01EE51latanoprost and netarsudil01.02.20192020
S01LA06brolucizumab01.02.20192020
V03AF11arginine and lysine01.02.20192020
V09IX13methionine (11C)01.02.20192020
1) Nasal formulations indicated for major depressive disorders. Parenteral formulations are classified in N01AX14.

Last updated: 2018-11-21